$CFRX Remember: Follow their Twitter for fastest updates. twitter.com/contrafectcorp Breakthrough designation decision is expected this quarter. Federated Investors: 3.1M shares Pfizer: 1.1M shares Oracle Investment: 450,000 shares Adage Capital: 290,000 shares 683 Capital: 250,000 shares BVF Partners: 200,000 shares Vanguard Group: 180,000 shares White Pine Capital: 100,000 shares With Breakthrough Designation, FDA fast track, and good results this is worth between $1.5-$2 Billion. CEO says $700M-$1.5B in annual sales. Applied for "Breakthrough Designation" FDA has 60 days to respond. PH2 showed tremendous response rate. Currently being used in France. There was a buyout offer but the Board turned it down. Shows confidence in the drug
  • 8
  • 3